Biological properties of (1→3)-β-d-glucan-based synthetic oligosaccharides

Journal of Medicinal Food

Volumn 14, Issue 4, 2011, Pages 369-376

  Saraswat Ohri, Sujata ^a   Vashishta, Aruna ^a   Vetvicka, Vaclav ^a   Descroix, Karine ^b,c,e   Jamois, Frank ^d   Yvin, Jean Claude ^d,f   Ferrières, Vincent ^b,c  

^a University of Louisville School of Medicine   (United States)

^b UNIV RENNES   (France)

^c UNIVERSITÉ EUROPÉENNE DE BRETAGNE   (France)

^d Laboratoires Goemar   (France)

^e UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^f AFI   (France)

Author keywords

(1 3) d glucans; immune reactions; oligosaccharides; phagocytosis

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MANNOSE; OLIGOSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ARTICLE; BREAST CANCER; CANCER CELL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SYNTHESIS;

ANIMALS; BETA-GLUCANS; CELL LINE, TUMOR; FEMALE; FIBROBLASTS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-2; INTERLEUKIN-4; INTERLEUKIN-5; INTERLEUKIN-6; MANNOSE; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; OLIGOSACCHARIDES; PHAGOCYTOSIS; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MURINAE;

EID: 79953202208     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2010.0081     Document Type: Article

References (35)

1. Novak M, Vetvicka V: Glucans as biological response modifiers. Endocr Metab Immune Disord Drug Targets 2009;9:67-75.
2. Bleicher P, Mackin W: Betafectin PGG-glucan: a novel carbohydrate immunomodulator with anti-infective properties. J Biotechnol Healthcare 1995;2:207-222.
3. Liang J, Melican D, Cafro L, et al.: Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int J Immunopharmacol 1998;20:595-614. (Pubitemid 28535144)
4. Patchen ML, Vaudrain T, Correira H, Martin T, Reese D: In vitro and in vivo hematopoietic activities of Betafectin PGG-glucan. Exp Hematol 1998;26:1247-1254. (Pubitemid 28541768)
5. Patchen ML, MacVittie TJ: Comparative effects of soluble and particulate glucans on survival in irradiated mice. J Biol Response Mod 1986;5:45-60. (Pubitemid 16167629)
6. Vetvicka V, Dvorak M, Vetvickova J, et al.: Orally-administered marine b1,3 glucan Phycarine stimulates both humoral and cellular immunity. Int J Biol Macromol 2007;40:291-298.
7. Vetvicka V, Vetvickova J: β-glucans as immunomodulators. J Am Nutr Assoc 2001;3:31-34.
8. Yoshino S, Watanabe H, Imano M, Yagi M, Suga T, Nakazawa S: Evaluation of efficacy for immune adjuvant (Lentinan(β-1,3- glucan))-containing supplementary food in patients with unresectable and recurrent gastric cancer. Biotherapy 2007;21:265-273. (Pubitemid 47280279)
9. Yadomae T: Structure and biological activities of fungal β-1,3- glucans [in Japanese]. Yakugaku Zasshi 2000;120:413-431. (Pubitemid 30317923)
10. Kogan G: (1-3,1-6)- β-d-Glucans of yeast and fungi and their biological activity. In: Studies in Natural Products Chemistry (Atta-ur-Rahman, ed.). Elsevier, Amsterdam, 2000, pp. 107-152.
11. Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD: β-Glucan-binding lectin site of complement receptor type 3 (CD11bCD18). J Immunol 1996;156:1235-1246.
12. Xia Y, Vetvicka V, Yan Y, Hanikyrova M, Mayadas T, Ross GD: The β-glucan-binding lectin site of mouse CR3 (CD11b=CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3β-opsonized target cells. J Immunol 1999;162:2281-2290. (Pubitemid 29288852)
13. Vetvicka V, Volny T, Saraswat-Ohri S, Vashishta A, Vetvickova J: Glucan and resveratrol complex-possible synergistic effects on immune system. Biomed Pap 2007;151:41-46.
14. Descroix K, Vetvicka V, Jamois F, Yvin J-C, Ferrières V: Synthesis of oligo-β-(1,3)-glucanyl-β-(1,3)-mannose and their immunostimulating properties. Bioorg Med Chem 2009;18:348-357.
15. Vetvicka V, Yvin J-C: Effect of marine β-1,3 glucan on immune reactions. Int Immunopharmacol 2004;4:721-730. (Pubitemid 38595529)
16. Jamois F, Ferrieres V, Guegan JP, Yvin JC, Plusquellec D, Vetvicka V: Glucan-like synthetic oligosaccharides-iterative synthesis of linear oligo-β-(1,3)-glucans and immunostimulatory effects. Glycobiology 2004;15:393-407. (Pubitemid 41214169)
17. Ross GD, Cain JA, Myones BL, Newman SL, Lachmann PJ: Specificity of membrane complement receptor type three (CR3) for β-glucans. Complement Inflamm 1987;4:61-74.
18. Ross GD, Vetvicka V: Stimulation of tumor-localized NK cell cytokine secretion by β-glucan priming of CR3 (CD11b=CD18) for cytotoxic recognition of tumor-restricted iC3β. Eur Cytokine Netw 1996;7:468.
19. Xia Y, Ross GD: Generation of recombinant fragments of CD11b expressing the functional β-glucan-binding lectin site of CR3 (CD11b=CD18). J Immunol 1999;162:7285-7293. (Pubitemid 29277702)
20. Abel G, Szollosi J, Chihara G, Fachet J: Effect of lentinan and mannan on phagocytosis of fluorescent latex microbeads by mouse peritoneal macrophages: a flow cytometric study. Int J Immunopharmacol 1989;11:615-621. (Pubitemid 19239435)
21. Holub M, Fornusek L, Vetvicka V, Chalupna J: Enhanced phagocytic activity of blood leukocytes in athymic nude mice. J Leukoc Biol 1984;35:605-615. (Pubitemid 14051757)
22. Falch BH, Espevik T, Ryan L, Stokke BT: The cytokine stimulating activity of 1-3-β-d-glucans is dependent on the triple helix conformation. Carbohydr Res 2000;329:587-596.
23. Salvador C, Li B, Hansen R, Cramer DE, Kong M, Yan J: Yeastderived β-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models. Clin Canc Res 2008;14: 1239-1247. (Pubitemid 351302573)
24. Zhang LYJ, Hwang PM, Kinzler KW, Vogelstein B: PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001;7:673-682. (Pubitemid 32706358)
25. Puthalakath H, Strasser A: Keeping killers on a tight lease: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002;9:505-512. (Pubitemid 34521178)
26. Lee DH, Kim C, Zhang L, Lee YJ: Role of p53, PUMA and Bax in wogonin-induced apoptosis in human cancer cells. Biochem Pharmacol 2008;75:2020-2033.
27. Middelburg R, de Haas RR, Dekker H, et al.: Induction of p53 up-regulated modulator of apoptosis messenger RNA by chemotherapeutic treatment of locally advanced breast cancer. Clin Cancer Res 2005;11:1863-1869. (Pubitemid 40471851)
28. DeHaan RD, Yazlovitshaya EM, Persons DL: Regulation of p53 target gene expression by cisplatin-induced extracellular signalregulated kinase. Cancer Chemother Pharmacol 2001;48:383-388. (Pubitemid 33027995)
29. Futami T, Miyagishi M, Taira K: Identification of a network involved in thapsigargin-induced apoptosis using a library of siRNA-expression vectors. J Biol Chem 2005;280:826-831. (Pubitemid 40165051)
30. Li J, Lee B, Lee AS: Endoplasmic reticulum stress-induced apoptosis: multiple pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA by p53. J Biol Chem 2006;281:7260-7270. (Pubitemid 43847494)
31. Hacker H, Karin M: Is NF-kappaB2=p100 a direct activator of programmed cell death? Cancer Cell 2002;2:431-433. (Pubitemid 41043946)
32. Wang Y, Cui H, Schroering A, et al.: NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat Cell Biol 2002;4:888-893. (Pubitemid 35331364)
33. Nilsson I, Hoffmann I: Cell cycle regulation by the Cdc25 phosphatase family. Prog Cell Cycle Res 2000;4:107-114.
34. Lavecchia A, Coluccia A, Di Giovanni C, Novellino E: Cdc25B phosphatase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem 2008;8:843-856.
35. Ito Y, Yoshita H, Urono T, et al.: Expression of Cdc25a and Cdc25b phosphatase in breast carcinoma. Breast Cancer 2004; 11:295-300.